학술논문
Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results from the Phase-3 Pivotal Trials
Document Type
Abstract
Author
Source
In The Journal of Allergy and Clinical Immunology February 2023 151(2) Supplement:AB130-AB130
Subject
Language
ISSN
0091-6749